Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05767021
Other study ID # 18551
Secondary ID I6T-MC-AMBZ2022-
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 17, 2023
Est. completion date March 31, 2025

Study information

Verified date June 2024
Source Eli Lilly and Company
Contact There may be multiple sites in this clinical trial. 1-877-CTLILL
Phone 1-317-615-4559
Email ClinicalTrials.gov@lilly.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 160
Est. completion date March 31, 2025
Est. primary completion date December 9, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Have an established diagnosis of UC for =3 months - Have confirmed diagnosis of moderately for severely active UC - Have current bowel urgency - Have demonstrated an inadequate response to, a loss of response to, or an intolerance to conventional or to biologic/Janus Kinase (JAK) inhibitor/sphingosine-1-phosphate (S1P) receptor modulator therapy for UC. Exclusion Criteria: - Have Crohn's disease (CD) - Have inflammatory bowel disease-unclassified, formerly known as indeterminate colitis, or - Have ulcerative proctitis, disease limited to the rectum, that is, distal to the recto-sigmoid junction, which lies approximately 10 to 15 centimeter (cm) from anal verge. - Have an inherited immunodeficiency syndrome or a monogenic cause of UC-like colonic inflammation - Have any history or current evidence of cancer of the gastrointestinal tract - Have active tuberculosis - Have HIV infection.

Study Design


Intervention

Drug:
Mirikizumab
Administered IV
Mirikizumab
Administered SC

Locations

Country Name City State
Belgium Universitair Ziekenhuis Gent - Gastro IBD Gent
Belgium UZ Leuven - E507 Studies IBD tav Tine Hermans Leuven
Czechia SurGal clinic s.r.o. Brno
Czechia Vojenska nemocnice Brno, Interni oddeleni Brno Czech Republic
Czechia Hepato-gastroenterologie HK, s.r.o. Hradec Kralove Hradec Králové
Czechia GastroJeka s.r.o Klatovy Czech Republic
Czechia MUDr. Gregar, s.r.o. Olomouc Olomoucký Kraj
Czechia PreventaMed, s.r.o. Olomouc
Czechia FN Ostrava, Interní Klinika Ostrava Czech Republic
France Chu Besancon Besancon
France CHU de LILLE - Bureau des ARCs Gastro - HPDD Lille Cedex
France Hospices Civils de Lyon - Hôpital Lyon Sud - ARC HGE bâtiment 3I Lyon - Pierre Benite
France Hôpital Saint-Eloi Pôle Digestif ,APEMAD - Recherche clinique Montpellier
France Clinique Jules Verne Nantes
France CHU Nantes Nantes Cedex 1
France Unité de Recherche Clinique (4èmeB) Nice Cedex 3
France Centre Hospitalier de Pau Pau Pyrénées-Atlantiques
France CHU Bordeaux - Hôpital Haut-Lévêque Pessac Gironde
France Chu de Reims - Hôpital Robert Debré Reims Cedex
France CHU Rennes - Hôpital Pontchaillou Rennes cedex 09 Ille Et Vilaine
France CHU de Saint-Etienne Saint Etienne Cedex 02
France Chru Nancy Brabois Vandoeuvre les Nancy
Germany DRK Kliniken Berlin Westend, Gastroenterologie, Studienbüro Berlin
Germany Praxis Dr. M. Mross - Gastroenterologie Berlin
Germany Universitätsklinikum Leipzig, Med. Klinik II Leipzig
Hungary Clinepert kft Budapest
Hungary Pannónia Magánorvosi Centrum Budapest
Hungary Semmelweis Egyetem, Belgyógyászati es Hematológiai Klinika Budapest
Hungary Bugat Pal Korhaz Gyongyos Heves
Hungary Clinfan Ltd. Gastroenterology Clinic Szekszard
Italy Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili) Brescia
Italy IRCCS Saverio de Bellis, National Institute of Gastroenterology Castellana Grotte
Italy Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico Milano
Italy Irccs Ospedale San Raffaele, Gastroenterologia/Ibd Unit, Settore G Piano -1 Milano
Italy Fondazione Policlinico Agostino Gemelli IRCCS_ CEMAD Roma
Italy Uoc Gastroenterologia - Policlinico Tor Vergata Roma
Italy IRCCS Istituto Clinico Humanitas- Centro Malattie Infiammatorie Intestinali Rozzano
Italy A.O.Ordine Mauriziano, SC Gastroenterologia, ambulatorio endoscopia digestiva Torino
Poland NZOZ Centrum Medyczne KERmed Bydgoszcz
Poland Vitamed Galaj I Cichomski sp.j. Bydgoszcz
Poland MZ Badania Slowik Zymla Sp.j. Knurów Slaskie
Poland Centrum Medyczne Plejady Krakow
Poland KRAKOWSKIE CENTRUM MEDYCZNE Sp. z o.o Krakow
Poland Topolowa Medicenter Ryszawa & Wspólnicy Sp.j. Krakow
Poland AmiCare Sp. z o.o. Sp. K. Lodz
Poland Bonifraterskie Centrum Medyczne sp. z o.o Lodz
Poland IP Clinic Lodz
Poland Med-GASTR SP. Z O.O., SP.K. Lodz
Poland Allmedica Badania Kliniczne Sp. z o.o. Sp. k. Nowy Targ
Poland Twoja Przychodnia Opolskie Centrum Medyczne Opole
Poland Solumed Centrum Medyczne Poznan Wielkopolskie
Poland Centrum Medyczne Medyk Rzeszow Subcarpathian
Poland Nowe Zdrowie-Ck, Kieltucki I Wspólnicy Sp. J. Staszów
Poland DC-MED Sp. z o.o. s.k. Swidnica
Poland Sonomed Sp. z o.o. Szczecin
Poland Twoja Przychodnia - Szczecinskie Centrum Medyczne Szczecin
Poland NZOZ FOR MED sp. z o.o. Wadowice
Poland Centrum Medyczne Oporow Wroclaw
Poland FutureMeds sp. z o. o. Wroclaw
Poland PlanetMed Sp.z o.o. Wroclaw
Poland Centrum Medyczne Kuba Med 2 Sp. z o.o. ETG Zamosc Zamosc
Slovakia Fakultná nemocnica s poliklinikou F. D. Roosevelta Banská Bystrica gastroenterologická ambulancia, II. Interná klinika SZU Banska Bystrica Slovak Republic
Slovakia ALIAN s.r.o. Bardejov Slovak Republic
Slovakia CLINIQ, s.r.o Bratislava Slovak Republic
Slovakia GASTRO AMBULANCIA, poliklinika Tahanovce Kosice Slovak Republic
Slovakia Fakultna nemocnica Nitra, Interna klinika Nitra Slovak Republic
Slovakia KM Management, spol. s.r.o Nitra Stare Mesto Slovak Republic
Slovakia Accout Center s.r.o. Sahy Slovak Republic
United Kingdom Fairfield General Hospital Bury Great Britain
United Kingdom King's College Hospital NHS Foundation Trust London
United Kingdom Clinical Research Unit, Royal Liverpool University Hospital Waltham Forest
United States Digestive Health Partners - Research Department Asheville North Carolina
United States Digestive Healthcare of Georgia Atlanta Georgia
United States Washington Gastroenterology Bellevue Washington
United States NY Scientific Brooklyn New York
United States Charlotte Gastroenterolgy & Hepatology Charlotte North Carolina
United States Charlottesville Medical Research Charlottesville Virginia
United States Clinical Research Institute of Michigan, LLC Chesterfield Michigan
United States Chevy Chase Clinical Research Chevy Chase Maryland
United States Central Florida Gastro Research Clearwater Florida
United States Optimed Research, LTD Columbus Ohio
United States Gastro One Cordova Tennessee
United States Atlanta Center for Gastroenterology, P.C. Decatur Georgia
United States Medical Research Center of Connecticut, LLC Hamden Connecticut
United States Biopharma Informatic, LLC Houston Texas
United States Clinical Trial Network Houston Texas
United States Houston Endoscopy And Research Center, LLC Houston Texas
United States Grand Teton Research Group, PLLC Idaho Falls Idaho
United States IU Health University Hospital Indianapolis Indiana
United States Encore Borland-Groover Clinical Research Jacksonville Florida
United States Citrine Institute for Research and Wellness Katy Texas
United States Tri-Cities Gastroenterology Kingsport Tennessee
United States Om Research, LLC Lancaster California
United States Dedicated Clinical Research Litchfield Park Arizona
United States AngioCardiac Care of Texas, PA McAllen Texas
United States GI Alliance/ Metairie Metairie Louisiana
United States Advanced Research Associates, LLC Miami Florida
United States Research Associates of South Florida Miami Florida
United States Paramount Medical Research & Consulting, LLC Middleburg Heights Ohio
United States Delta Research Partners Monroe Louisiana
United States Gastroenterology Health Partners New Albany Indiana
United States Central Sooner Research Norman Oklahoma
United States California Medical Research Associates, Inc. Northridge California
United States Care Access Research - Ogden Ogden Utah
United States Digestive System Healthcare Pasadena Texas
United States LinQ Research, LLC Pearland Texas
United States University Gastroenterology Providence Rhode Island
United States Gastroenterology Research of San Antonio San Antonio Texas
United States Southern Star Research Institute, LLC San Antonio Texas
United States Clinical Applications Laboratories, Inc. San Diego California
United States Gastroenterology Associates of Texas - Denise Rodriguez Sugar Land Texas
United States Arizona Digestive Health - Sun City Sun City Arizona
United States Washington Gastroenterology dba GI Alliance Tacoma Washington
United States GCP Clinical Research, LLC Tampa Florida
United States International Center for Research LLC Tampa Florida
United States Cotton-O'Neil Clinical Research Center, Digestive Health Topeka Kansas
United States Tyler Research Institute, LLC Tyler Texas
United States GI Alliance Research Webster Webster Texas
United States Innovo Research:Wilmington Health Wilmington North Carolina
United States West Michigan Clinical Research Center Wyoming Wyoming

Sponsors (1)

Lead Sponsor Collaborator
Eli Lilly and Company

Countries where clinical trial is conducted

United States,  Belgium,  Czechia,  France,  Germany,  Hungary,  Italy,  Poland,  Slovakia,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline in Bowel Urgency Severity Urgency Numeric Rating Score (UNRS) Baseline, Week 12
Secondary Change from Baseline in Bowel Urgency Frequency Baseline, Week 12
Secondary Percentage of Participants Achieving Clinically Meaningful Improvement in Bowel Urgency Frequency Baseline to Week 12
Secondary Change from Baseline in Stool Deferral Time Baseline, Week 12
Secondary Percentage of Participants Achieving Clinically Meaningful Improvement of Stool Deferral Time Week 12
Secondary Percentage of Participants achieving Both Clinical Remission, Based on the modified Mayo Score and a UNRS score of =1 Week 12
Secondary Percentage of Participants achieving Both Clinical Response, Based on the modified Mayo Score and a UNRS score =3 Points of Improvement from Baseline Week 12
Secondary Pairwise Correlations between the UNRS, Bowel Urgency Frequency, Stool Deferral Time, and Absorbent Product Use Measures Baseline to Week 12
Secondary Pairwise Correlations between Change in UNRS, Bowel Urgency Frequency, Stool Deferral Time, and Absorbent Product Use Measures Baseline to Week 12
Secondary Correlation between the UNRS, Bowel Urgency Frequency, Stool Deferral Time, and Absorbent Product Use Measures, with Quality of Life (QoL)/Functional Outcome Measures and Ulcerative Colitis (UC) Symptom Measures Baseline to Week 12
Secondary Correlation between Change in UNRS, Bowel Urgency Frequency, Stool Deferral Time, and Absorbent Product Use Measures, with Change in QoL/Functional Outcome Measures and UC Symptom Measures Baseline to Week 12
See also
  Status Clinical Trial Phase
Recruiting NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Not yet recruiting NCT05953402 - A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT03950232 - An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04314375 - Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Phase 4
Active, not recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Active, not recruiting NCT06221995 - Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Recruiting NCT06071312 - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach Phase 1/Phase 2
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2